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Abstract A previous study showed that a single nucleo-
tide polymorphism (SNP), -1438G/A (rs6311), found in
the transcriptional control region of the gene that encodes
the serotonin-receptor 2A (HTR2A) was associated with
obsessive–compulsive disorder (OCD) in a sample of
children and adolescents. In this study, we reanalyzed the
association of this SNP with OCD in an enlarged popula-
tion of 136 cases (55 previous ? 81 new cases) and com-
pared them to 106 newly recruited, healthy, age-matched
controls. We also investigated whether this SNP or its copy
number variations (CNV) was associated with OCD
severity and age of onset. The CNV was analyzed in a
DNA region located near rs6311. The results confirmed the
association between the A-allele and early onset OCD in
children and adolescents, with an odds ratio (OR) of 1.69
[95% CI (1.17, 2.46); p = 0.005]. Strikingly, we found that
carriers of one copy (deletion) of the CNV were associated
with a very early onset OCD (2.5 years earlier than the
typical onset), and they had increased CY-BOCS scores
(8.7 points higher compared to ‘‘normal’’ CNV and
duplications); which is related to increased severity of
OCD symptoms (p = 0.031; p = 0.004, respectively).
Compared to the normal CNV and duplications, the asso-
ciation between the deletion and OCD showed an OR of
7.56 [95% CI (1.32, 142.84); p = 0.020]. These results
pointed to the functional importance of this promoter
region of HTR2A; it influenced the occurrence, the onset,
and the severity of OCD.
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Introduction
Obsessive–compulsive disorder (OCD) is a heterogeneous
psychiatric disorder characterized by clinically significant,
recurrent, intrusive, and disturbing thoughts (obsessions),
accompanied by repetitive, stereotypic behaviors, usually
associated with anxiety or dread (compulsions) (American
Psychiatric Association 1996). According to the National
Comorbidity Survey Replication, the median age of OCD
onset is 19 years. However, symptoms of OCD often
begin during childhood or adolescence; 21% of all cases
start experiencing symptoms by age 10 years old (Kessler
et al. 2005). The early onset OCD often develops a
chronic course and has a poor long-term outcome.
According to a review of twin studies (van Grootheest
et al. 2005), the authors concluded that the heritability for
obsessive compulsive symptoms ranges from 0.45 to 0.65
in children and from 0.27 to 0.47 in adults. Grados and
colleagues (2007) summarized that family studies showed
OCD five- to sevenfold more frequent in relatives of
patients than in relatives of controls. In accord to the
results of twin studies, in family studies, the earlier age of
onset of OCD in the index patients was correlated with
a higher prevalence of OCD in first-degree relatives
(Walitza et al. 2010). However, there is a wide range of
prevalence rates of OCD in first-degree relatives across
different studies, which merits discussion. The definition
of early onset OCD differs among studies at the cut-off
for age of onset; under 7 years of age was the lowest and
under 18 years of age was the highest age as definition
criteria. Furthermore, e.g. including different comorbidi-
ties as tic-disorders could have some effects on formal
and molecular genetic results. Heterogeneity of the phe-
notype, the young age of siblings in studies of childhood
OCD patients may result in an over/underestimation of
the prevalence of OCD in relatives.
Dysfunction of the serotonin (5-HT) system has been
implicated in OCD and is thought to contribute to behav-
ioral traits, like perfectionism, obsessiveness, anxiety, and
depression (Serretti et al. 2007; Zohar et al. 2000). Selec-
tive serotonin re-uptake inhibitors (SSRI; e.g. fluoxetine)
that block the serotonin transporter represent the most
effective pharmacological treatment of OCD, early onset
OCD, and anxiety disorders (Geller et al. 2003; Pediatric
OCD Treatment Study (POTS) Team 2004). Therefore,
most genetic association studies in OCD have investigated
genes related to serotonergic signaling. Although there is
extensive evidence that the heritability of early onset OCD
is higher than the heritability of adult onset OCD associ-
ation studies in early onset OCD are comparably rare.
Our group previously conducted an association study
within a case–control design to determine whether early
onset OCD was associated with the single nucleotide
polymorphism (SNP), -1438A/G (rs6311), in the seroto-
nin receptor 2A (HTR2A) promoter (Walitza et al. 2002).
We detected a significant association between OCD and the
A-allele of 1438A/G (Walitza et al. 2002). Our results were
in accordance with the results from a study conducted by
Enoch and colleagues in adult patients with OCD as well as
in early onset OCD determined retrospectively (Enoch
et al. 1998, 2001). However, several other case–control
association studies on adult OCD patients (Denys et al.
2006; Saiz et al. 2008a; Tot et al. 2003) reported no
association with SNP rs6311 as well as negative trans-
mission-disequilibrium tests (Dickel et al. 2007). Similarly,
several association studies for the synonymous T102C
(rs6313) variant, which was reported to be in complete
linkage disequilibrium with rs6311 in different populations
(Spurlock et al. 1998; Meira-Lima et al. 2004; Martinez-
Barrondo et al. 2005; Saiz et al. 2008b), reported con-
flicting results in adult OCD patients (Tot et al. 2003;
Meira-Lima et al. 2004; Hemmings et al. 2003; Frisch et al.
2000; Saiz et al. 2008a; Hemmings et al. 2006). Since Kato
and colleagues (1996) presented evidence for genomic
imprinting (complete inactivation of one allele) of the
HTR2A, several studies investigate the effects of the
5HTR2A imprinting on expression, but up to now con-
flicting results have been reported. Bunzel and colleagues
(1998) showed in 4 out of 18 post-mortem brain tissues
monoallelic expression of the HTR2A due to polymorphic
imprinting in the brain. Other authors suggested that
HTR2A is unlikely to have any polymorphisms that alter
gene expression in the brain in an allele-dependent pattern
(Bray et al. 2004). But CpG sites, which are apparently
potential target regions for methylation have been detected
within the rs6311 polymorphism are relevant for expres-
sion pattern (Bray et al. 2004; Polesskaya et al. 2006). In
contrast to the findings of Bunzel et al. (1998), de Luca
et al. (2007) found no evidence of genomic imprinting in a
sample of 29 heterozygous psychotic patients and 16 het-
erozygous controls. The authors concluded that complete
polymorphic imprinting of the HTR2A gene may be a rare
event. Although there are conflicting perspectives regard-
ing imprinting of the HTR2A we decided to enlarge our
previous sample with early onset OCD to reinvestigate the
association with the 5HT2A promoter polymorphism. In
parallel, we focused on a copy number variation (CNV)
near the rs6311promoter region. Recent investigations have
implicated de novo and/or rare CNVs as potentially path-
ogenic factors in attention-deficit/hyperactivity disorder
(ADHD) (Williams et al. 2010; Lesch et al. 2011), autism
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(Stankiewicz and Lupski 2010; Pinto et al. 2010), and
schizophrenia (Lee et al. 2010). Rare CNV is defined
having lower frequency than 1% in the population, while
common CNV also referred as polymorphism has higher
frequency (Beckmann et al. 2007). The duplication or
deletion process of CNVs can disrupt a variable number of
genes, which can result in alternate gene products or
changes in gene dosage. Moreover, the disruption of reg-
ulatory regions in the genome can lead to altered gene
expression, and this may contribute to disease predisposi-
tion. Given the highly heritable and variable nature of
OCD, we hypothesized that individual, CNVs near the SNP
rs6311 might contribute to OCD risk and severity. There-
fore, after searching for CNVs reported in the Database of
Genomic Variants (DGV; http://projects.tcag.ca/variation/)
site as well as other CNVs in the HTR2A gene or in its
vicinity, that resulted in no known CNV, we aimed to
detect new putative CNV using the pre-designed TaqMan
CNV-assay (Applied Biosystems Co., Germany) that cor-
respond to the nearest CNV to the SNP (68-bp upstream of
SNP rs6311, while amplicon size was 100 bp) and still on
the promoter region (Fig. 1), assuming that this region is of
functional relevance.
In the present study, we extended the number of patients
included in our previous study (Walitza et al. 2002) and
also included new independent controls. We aimed to
confirm our previous results of the association between the
rs6311 polymorphism and early onset OCD. In addition,
we aimed to investigate the association between early onset
OCD and the not yet described CNV located near SNP
rs6311 on the HTR2A promoter.
Materials and methods
Subjects
The study sample comprised patients that had received
inpatient treatment at the Department of Child and Ado-
lescent Psychiatry of the Universities of Wu¨rzburg, Mar-
burg, Aachen, and Freiburg. All patients and healthy
controls were of German ethnicity. All participants and the
parents of minors gave written informed consent. The
ethics committees of all participating universities approved
the study.
Patients fulfilled the diagnostic criteria for current OCD
according to the Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) (1996) and the
International Statistical Classification of Diseases and
Related Health Problems, 10th Revision (ICD-10) (Dilling
et al. 1996). To describe the broad range of clinical fea-
tures, we ascertained systematically initial symptoms from
baseline with psychopathology schemes as CASCAP-D
(Do¨pfner et al. 1999). To assess the criteria for OCD and
Fig. 1 Alignment of CNV and SNP rs6311 on the HTR2A promoter
sequence and their effects on transcription factors. a The alignment of
HTR2A on chromosome 13. b The HTR2A gene alignment with its
promoter region (not to scale). c The promoter region with the CNV
and rs6311 alignment (not to scale); the indicated transcription factors
may be affected according to PROMO version3 (http://algenn-
lsi.ups.es). Red G-allele, green A-allele, ? gain, - loss, of tran-
scription factors (according to Piva et al. 2010)
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comorbid psychiatric disorders, both patients and parents
were interviewed separately with the semi-structured
diagnostic interview of psychiatric disorders in children
and adolescent (Kinder-DIPS; children and parents ver-
sion) (Unnewehr et al. 1995). The Kinder-DIPS is used to
assess a wide range of psychiatric disorders in childhood
and adolescence, including ADHD, and conduct and
oppositional-, anxiety-, affective-, eating- and tic-disorders,
diagnosed according to the criteria of the ICD-10 (Dilling
et al. 1996). The Kinder-DIPS further includes a general
clinical screening component to assess substance use,
abuse, psychosis and somatic diseases. Autistic spectrum
disorders were screened within the ascertainment of psy-
chopathology (CASCAP-D) (Do¨pfner et al. 1999).
The Children’s Yale-Brown Obsessive Compulsive
Scale (CY-BOCS) (Scahill et al. 1997) was used to assess
further characteristics and severity of OCD. A summary
score above 16 points was determined to be the cut-off for
clinical impairment caused by OCD symptomatology; a
score of 38 points was the maximum for describing
severity according to the CY-BOCS. Of note, the DSM-IV
does not require children to fulfill the criterion of insight
regarding the irrationality of the symptoms. This may result
in low summary scores; therefore, it is possible that the
CY-BOCS evaluations underestimated the true severity of
symptomatology. For diagnostic assessments of present
and lifetime Tourette’s Syndrome and tic-disorders, we
used the adapted German version (Hebebrand et al. 1997)
of the Child and Adult Schedule for Tourette and Other
Behavioral Syndromes (STOBS), according to Pauls et al.
(1991).
All interviews were performed by senior clinicians of
the university clinics for child and adolescent psychiatry.
Subjects with comorbid disorders were only included in the
study when the OCD symptoms were most prominent,
based on two criteria: (1) OCD had to predate the onset of
the comorbid disorders (except ADHD), and (2) two senior
clinicians independently diagnosed the predominance of
the OCD symptoms.
Exclusion criteria for patients were: lifetime history of
psychotic disorders, Gilles-de-la-Tourette’s syndrome and
chronic tic-disorder, autistic spectrum disorder (e.g.
infantile autism, atypical autism, Asperger’s syndrome),
alcohol dependence, or mental retardation (IQ \ 70).
The patient sample consisted of 136 patients (children
and adolescents). The patient sample was a superset that
comprised 55 children with OCD from a previous study
(Walitza et al. 2002), plus 81 newly recruited children with
OCD.
In a previous case–control study regarding the
-1438G/A polymorphism in early onset OCD (Walitza
et al. 2002), the control group consisted of students that
were older than the patients. For this study, we recruited
106 healthy German children from the Department of
Child and Adolescent Psychiatry of the University of
Wu¨rzburg to use as new independent controls. They were
screened with the Child Behavior Checklist (CBCL)
(Do¨pfner et al. 1991) and a validated German depression
self-rating inventory (DIKJ) (Stiensmeier-Pelster et al.
2000). All controls and their mothers were interviewed
with the Schedule for Affective Disorders and Schizo-
phrenia for school-aged children (Kiddie-Sads) (Kaufman
et al. 1997). The intelligence level was assessed with the
Culture Fair Test (CFT 1/20) (Cattell et al. 1997).
Exclusion criteria for participation of controls were: any
severe somatic or neurological disease; any psychiatric
diagnosis according to the Kiddie-Sads; a DIKJ score that
exceeded the threshold of 18 for clinically relevant
depressive symptoms; any T-score above 63 on the
internalizing, externalizing, or total score of the CBCL; or
an IQ below 80.
Genotyping for the HTR2A -1438 A/G polymorphism
Genomic DNA was extracted from whole blood with the
desalting Proteinase K methodology (Miller et al. 1988).
Genotyping for the -1438 A/G polymorphism (rs6311)
(location 47,471,478 on the GRCh37; 13q14 q21) was
conducted with the TaqMan SNP genotyping assay
(Assay no. C-8695278-10; Applied Biosystems Co.) on the
iCycler iQ Real-Time thermocycler (BioRad Laboratories
Inc., Germany), according to manufacturer instructions.
Genotypes were assessed according to the Allelic dis-
crimination method with the iCycler IQ software (version
3.1.7050; BioRad Laboratories).
CNV analysis
The CNV located 68 bp upstream of SNP rs6311 (location
47,471,310-47,471,410 on GRCh37; 13q14.2a; amplicon
size 100 bp; Fig. 1) was analyzed with the TaqMan Copy
Number Assay (Assay no. Hs06366812_cn; Applied Bio-
systems Co.) on the iCycler iQ Real-Time thermocycler
(BioRad Laboratories Inc.), according to manufacturer
instructions. Each sample was adjusted to 20 ng genomic
DNA per well. The TaqMan Copy Number Reference
assay for RNase P was used for normalization. Four rep-
licates were run per sample. The CNV per sample were
evaluated by the Cycles threshold (CT) values assigned
with the CopyCaller software (version 1.0; Applied Bio-
systems Co.). A ‘‘normal‘‘CNV was defined as two copies;
a ‘‘low’’ CNV was defined as B1 copy (deletion); and a
‘‘high’’ CNV was defined as C3 copies (duplication). For
each sample, an independent replication of the assay was
conducted in order to eliminate false determinations of
CNV.
510 S. Walitza et al.
123
Statistical analysis
All statistical tests were two-sided with an alpha-level of
0.05. The results were unadjusted for multiple testing,
because the analysis was exploratory and the number of
tests was comparably small. The association study of the
SNP was a replication study. Assuming an OCD prevalence
of 2% and a disease allele frequency of 50%, we have a
power of 91.1% for detecting an odds ratio (OR) of at least 2
using Armitage’s trend test and only the 81 new patients
(Slager and Schaid 2001). This was analyzed primarily by
omitting the cases analyzed in the previous study that gave
similar significant results (data not shown). Secondly, we
analyzed the complete sample. All confidence intervals
were 95% profile likelihood intervals (Pawitan 2001).
Gender and age distributions were compared with
Fisher’s exact test and the Student’s t test, respectively.
Differences in average OCD onset and severity (measured
by the CY-BOCS score) were assessed with one- and two-
way ANOVAs for separate and simultaneous comparisons,
respectively. In the case–control analysis, discrepancies in
SNP and CNV distributions were separately tested with
Armitage’s trend test and Fisher’s exact test, respectively
(Sasieni 1997). Logistic regression for a simultaneous
association analysis of SNP and CNV with OCD assumed
an additive model for SNP and an unrestricted model for
CNV. An additional interaction of SNP with gender was
tested with the Student’s t test.
The computations were performed with the statistical
computing software R (R Development Core Team 2010),
version 2.11.0.
Results
Demographic data
The study population included slightly more males than
females in both the OCD and the healthy control groups
(p = 0.51; Table 1). The healthy controls were signifi-
cantly younger than the patients with OCD (p \ 0.0001;
Table 1); however, the average age of the controls was not
significantly different from the average age of the patients
at OCD onset (p = 0.21; Table 1). For the comorbidities
and gender data, see Table 1.
Case–control analysis of the HTR2A -1438 A/G
polymorphism and CNV
The association between SNP rs6311 and OCD was first
analyzed in only the 81 newly recruited patients with OCD
(those not included in the previous study (Walitza et al.
2002). There was a significant difference between the
genotype distributions of controls and these OCD cases
(p = 0.030). Note that the previous study, with a different
control group and a smaller OCD group, also reported a
significant association between genotype and OCD
(p = 0.046). When all 135 available cases with SNP
information were included, the association was highly
significant (p = 0.007). We also found that patients with
early onset OCD showed a higher frequency of the AA
genotype (19.3%) compared to the healthy controls (16%)
(Table 2). The estimated OR for the A allele was 1.69
[95% CI (1.17, 2.46); p = 0.005], adjusted for CNV.
Assuming an additive effect of the A allele, this indicated
that the risk of OCD was increased by 69% in patients with
the heterozygous GA genotype and by 286% for the
homozygous AA genotype.
The association (adjusted for SNP) between the HTR2A
CNV (‘‘low’’ vs. ‘‘normal/high’’) and OCD was also sig-
nificant (p = 0.020). The SNP-adjusted OR estimated for a
‘‘low’’ CNV relative to a ‘‘normal/high’’ CNV was 7.56
Table 1 Demographic data
N Frequency (%)
136 patients
Gender
Male 77 56.6
Female 59 43.4
Age at investigation 13 ± 2.9 years (range 4.7–17.9 years)
Age at onset 11.1 ± 3.2 years (range 3–17.4 years)
Comorbid diagnosis
None 74 54.4
ADHD 15 11.0
Anxiety disorders 10 7.4
Depression disorders 8 5.9
Eating disorders 5 3.7
Conduct disorders 4 2.9
Others* 7 5.1
Tic-disorder** 13 9.6
106 controls
Gender
Male 65 61.3
Female 41 38.7
Age 11.6 ± 2.6 years (range 5.1–17.8 years)
ADHD attention-deficit hyperactivity disorder
* Comorbidities as dyslexia, enuresis, histrionic personality disorder
and behavioral and emotional disorders (as separation anxiety disor-
der of childhood, social anxiety disorder of childhood, depressive
conduct disorder, elective mustism), which occur, respectively, only
in one of the patients
** Lifetime-diagnosis of tic-disorder according to STOBS, without
Tourette’s syndrome
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[95% CI (1.32, 142.84)]. We did not find a significant
gender effect in our case–control analysis (p = 0.72).
HTR2A -1438 A/G polymorphism and CNV
associations with age of onset and severity of OCD
The HTR2A genotype was not significantly associated with
age of onset or severity of OCD (Table 3a). In addition,
there was no significant difference between ‘‘normal’’ and
‘‘high’’ CNV with respect to age of onset or severity (t test
p = 0.47 and p = 0.30, respectively). Because we
hypothesized that the deletion (‘‘low’’ CNV) would affect
the phenotype by impairing the function of the promoter
activity, we pooled the ‘‘normal’’ and ‘‘high’’ data into a
joint ‘‘normal/high’’ CNV group for comparisons to the
‘‘low’’ CNV group (Table 3b). This analysis method
revealed a significant association between ‘‘low’’ CNV and
the age of onset (p = 0.031); the estimated average age of
onset was 2.5 years earlier than that of the ‘‘normal/high’’
group [95% confidence interval (CI): (0.2 years,
4.8 years)]. Similarly, we observed a significant associa-
tion between ‘‘low’’ CNV and the OCD severity measured
with CY-BOCS scores (p = 0.004); the estimated average
severity score was 8.7 points higher than that of the
‘‘normal/high’’ group [95% CI: (2.9 points, 14.5 points)].
Discussion
In this study, we confirmed the previously described
association between the A allele of SNP rs6311 and early
onset OCD (Walitza et al. 2002; Enoch et al. 2001). We
estimated that the OR per A allele was 1.69 [95% CI (1.17,
2.46)] for early onset OCD, but we found no significant
association between the A allele of SNP rs6311 and age of
onset or OCD severity. This might be due to the fact that
the OCD population in this study contained only patients
Table 2 Frequencies of SNP rs6311 genotypes and CNV sizes in
patients with early onset OCD and healthy controls
Controls
N (frequency %)
OCD
N (frequency %)
Genotype (rs6311)
GG 54 (50.9) 39 (28.9)
GA 35 (33.0) 70 (51.9)
AA 17 (16.0) 26 (19.3)
Fisher’s exact test p = 0.002
Armitage’s test for trend p = 0.007
Two-sided asymptotic
(adjusted for CNV-pooled)
p = 0.005
CNV
‘‘Normal/high’’ 105 (99.1) 127 (94.1)
‘‘Low’’ 1 (0.9) 8 (5.9)
Fisher’s exact test p = 0.082
Two-sided asymptotic
(adjusted for SNP)
p = 0.020
One sample missing for the genotyping and one for CNV from
technical reasons
Table 3 Age at onset and severity of OCD, based on the SNP rs6311 genotype (A) and the CNV size (B)
A Genotype (rs6311) Age at onset
(years)
(mean ± SD)
N Missing CY-BOCS
(score)
(mean ± SD)
N Missing
GG 11.0 ± 3.3 38 1 23.9 ± 8.4 34 5
GA 10.9 ± 3.3 65 5 21.7 ± 7.0 66 4
AA 11.7 ± 2.6 25 1 21.0 ± 8.4 26 0
One-way ANOVA p = 0.55 p = 0.28
Two-way ANOVA (adjusted for CNV) p = 0.48 p = 0.29
Two-way ANOVA (adjusted for CNV-
pooled)
p = 0.44 p = 0.33
B CNV Age at onset
(years)
(mean ± SD)
Estimate
(95% CI)
(years)*
N Missing CY-BOCS (score)
(mean ± SD)
Estimate
(95% CI)
(score)*
N Missing
‘‘Normal/high’’ 11.2 ± 3.0 120 7 21.7 ± 7.6 119 8
‘‘Low’’ 8.8 ± 4.8 -2.5 (-0.2; -4.8) 8 0 30.6 ± 3.7 8.7 (2.9; 14.5) 7 1
One-way ANOVA p = 0.036 p = 0.003
Two-way ANOVA* p = 0.031 p = 0.004
One sample missing for the genotyping from technical reasons
One sample missing for the CNV from technical reasons
* Estimates and confidence intervals (CIs) are adjusted for SNP
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with very early onset of the disease (average age of onset
was 11.1 ± 3.2 years, range 3–17.4 years). Thus, we could
not rule out an age dependent association for the-rs6311 A
allele. The association found in this study, without age
dependence, could be consequence of polymorphism
influencing HTR2A gene expression through the promoter
activity. An extensive reporter gene assay suggested that
the rs6311 SNP modulated HTR2A promoter activity
(Parsons et al. 2004); however, another study on the effect
of the rs6311 SNP on promoter activity revealed no sig-
nificant difference in expression of HTR2A mRNA
(Spurlock et al. 1998).
Several studies on the polymorphic imprinting have
presented some conflicting results regarding monoallelic
expression of HTR2A (Bunzel et al. 1998; Kato et al. 1996;
Fukuda et al. 2006; Myers et al. 2007). Nevertheless, we
investigated whether the rs6311 polymorphism on the
promoter confirm association of previous findings in very
early onset OCD, since current findings do show that
specifically this particular SNP has transcriptional effects
on the gene. A recent study reported an in silico selection
of phenotypes that reflected different polymorphisms in the
HTR2A gene (Piva et al. 2010). The SNP rs6311 was found
to cause loss of the E2F1 transcription factor site and the
gain of two other transcription factor sites (HAND1E47
and SMAD; see Fig. 1). Another investigation of epige-
netic factors affected by rs6311 revealed that a newly
created E47-binding site (A-allele), a glucocorticoid
receptor-binding site at position -1420, and an Sp1-bind-
ing site at CpG methylation site ?1224 caused alterations
in methlylation rates at both -1420 and -1439 sites
(Falkenberg et al. 2011). Therefore, modifiers should be
taken into account in functional studies.
One problem with genetic analyses is the inability to
completely match a control group or minimize ethnic dif-
ferences between patients and controls. In the present
study, we included 136 German children and adolescents
with early onset OCD, of which 107 patients were children
from Wu¨rzburg, Germany. All patients and controls were
of German origin. Furthermore, all 106 healthy German
children were also recruited at the Department of Child and
Adolescent Psychiatry of the University of Wu¨rzburg;
therefore, we assumed that we were able to minimize
ethnic stratification.
We also found that one copy (deletion) of a CNV located
near the rs6311 was associated with very early onset OCD
and an increased CY-BOCS score, which was related to
enhanced symptom severity. Of note, the frequency of this
deletion in our OCD group (n = 8) was increased compared
to that in the healthy controls (n = 1). Since this CNV is not
yet reported in any platform such as DGV or any publica-
tion, little is known about its frequency or size. From our
findings one could assume that according to its frequency in
control group that it is a rare CNV, but concerning the size
further analysis should be conducted up/downstream the
amplicon location. Characterizations of CNVs and their
associated polymorphisms are important, because they may
provide key links to understanding of the genetic basis of
quantitative traits and the different susceptibilities to psy-
chiatric diseases. An initial study that explored the effects of
CNVs on gene expression in lymphoblastoid cell lines from
human populations reported that changes in copy number
explained nearly 20% of the detected gene expression var-
iation (Stranger et al. 2007). This was suggested to result
from altered dosages of genes that mapped within CNVs;
however, it may also potentially result from the impact of
CNVs on neighboring genes (Stranger et al. 2007). Recent
studies have shown that CNVs can influence the expression
of genes both within the CNV and outside the CNV, in the
vicinity of up to half a megabase (Henrichsen et al. 2009). It
was suggested that, for disorders like Williams–Beuren
(WBS; MIM 194050), Prader–Willi (MIM 176270), Ang-
elman (MIM 105830), and DiGeorge/velocardio-facial
syndromes (DG/VCFS; MIM 188400), patients with
duplications might have different clinical syndromes and
milder phenotypic features than those with deletions. This
might be explained by the fact that excess information tends
to be less detrimental to the organism than a deficiency
(Zhang et al. 2009). This effect might explain our obser-
vations of the effect that the ‘‘low’’ CNV had on the HTR2A
promoter region; this effect might also influence promoter
activity. A potential mechanism might be the loss of tran-
scription factor sites within the CNV deletion (Fig. 1).
However, this theory requires further investigation.
Limitations of the present study: the small sample size is
one of the main limitations of the study. Therefore, we
believe that the relatively narrow phenotype (e.g. early
onset OCD, without Tourette’s syndrome) as one of the
strengths of the study. A limitation could be also that we
have not used a special interview to exclude all autistic
spectrum disorders. For future studies, we recommend to
use interviews as the Kiddie-SADS in a recent version with
a separate interview of autistic symptoms according to
DSM-IV. As the HTR2A is imprinted, the results of the
association studies (patients compared to controls) cannot
be interpreted without caution. Nevertheless, these repli-
cated findings of association of the 5HT2A promoter
polymorphism with early onset OCD and with other psy-
chiatric disorders lead us to the CNV analysis in the
5HT2A promoter region, which showed interesting and
promising findings. Further independent and extended
studies of the CNV as well as the SNP analysis in early
onset OCD, but also in related disorders need to be per-
formed. These findings may suggest additional applications
for investigating the genomic effects associated with OCD
in large-scale populations.
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